Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 163Lung Neoplasms 53Neoplasms 14Neoplasm Metastasis 10NSCLC 10Brain Neoplasms 10Carcinoma 9Meningeal Carcinomatosis 6Colorectal Neoplasms 5Bronchial Neoplasms 5Thoracic Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Lung Diseases 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Prostatic Neoplasms 2Noonan Syndrome 2Non Small Cell Lung Cancer Metastatic 2

Interventions

pembrolizumab 2toripalimab 1sintilimab 1pemigatinib 1osimertinib 1durvalumab 1Vinorelbine 1Platinum Compounds 1Nivolumab 1Ipilimumab 1Drug Therapy 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Non Small Cell Lung Cancer × osimertinib × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡